Abstract
The recombinant antibodies in single-chain format (scFv) have found broad applications in both therapeutic and diagnostic fields. Tumour-associated antigens (TAAs) are proteins or other molecular species expressed in a specific tumour type, that can be targeted for diagnostic and immunotherapy purposes. The possibility of obtaining highly selective and efficacious scFvs makes them appropriate tools to target TAAs. The approach utilised for targeting depends on the nature of TAAs and their cell localisation. Tumour antigens displayed on the cell surface can be recognised by scFvs coupled to radioisotopes, toxins and enzymes to be used in cancer diagnosis and therapy. Intracellular tumour antigens can be targeted by scFvs expressed as “intracellular antibodies”. This review reports the existing scFv-based formats, hints of their generation and pharmacokinetics, and a description of the most promising TAAs. It also provides an update of in vitro, preclinical and clinical studies using scFvs against TAAs for cancer diagnosis and treatment, with their merits and limits.
Keywords: Single-chain antibody fragments, tumour-associated antigens, recombinant antibodies, intrabodies, cancer diagnosis, cancer therapy, targeted immunotherapy
Current Medicinal Chemistry
Title: Antibodies in Single-Chain Format Against Tumour-Associated Antigens:Present and Future Applications
Volume: 17 Issue: 17
Author(s): L. Accardi and P. Di Bonito
Affiliation:
Keywords: Single-chain antibody fragments, tumour-associated antigens, recombinant antibodies, intrabodies, cancer diagnosis, cancer therapy, targeted immunotherapy
Abstract: The recombinant antibodies in single-chain format (scFv) have found broad applications in both therapeutic and diagnostic fields. Tumour-associated antigens (TAAs) are proteins or other molecular species expressed in a specific tumour type, that can be targeted for diagnostic and immunotherapy purposes. The possibility of obtaining highly selective and efficacious scFvs makes them appropriate tools to target TAAs. The approach utilised for targeting depends on the nature of TAAs and their cell localisation. Tumour antigens displayed on the cell surface can be recognised by scFvs coupled to radioisotopes, toxins and enzymes to be used in cancer diagnosis and therapy. Intracellular tumour antigens can be targeted by scFvs expressed as “intracellular antibodies”. This review reports the existing scFv-based formats, hints of their generation and pharmacokinetics, and a description of the most promising TAAs. It also provides an update of in vitro, preclinical and clinical studies using scFvs against TAAs for cancer diagnosis and treatment, with their merits and limits.
Export Options
About this article
Cite this article as:
Accardi L. and Di Bonito P., Antibodies in Single-Chain Format Against Tumour-Associated Antigens:Present and Future Applications, Current Medicinal Chemistry 2010; 17 (17) . https://dx.doi.org/10.2174/092986710791111215
DOI https://dx.doi.org/10.2174/092986710791111215 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Photoinduced Controlled-Release Drug Delivery Systems for Applications in Nanomedicine
Current Organic Chemistry A Systems Biology Road Map for the Discovery of Drugs Targeting Cancer Cell Metabolism
Current Pharmaceutical Design Non-Photoinduced Biological Properties of Verteporfin
Current Medicinal Chemistry Evaluation of Effect of Triterpenes and Limonoids on Cell Growth, Cell Cycle and Apoptosis in Human Tumor Cell Lines
Anti-Cancer Agents in Medicinal Chemistry NO to Breast: When, Why and Why Not?
Current Pharmaceutical Design Acknowledgements to Reviewers
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Targeted Therapies in Oncology (Guest Editor: Monica M. Mita)]
Current Drug Targets The Need for Improvement of the Treatment of Advanced and Metastatic Cervical Cancer, the Rationale for Combined Chemo-Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry Recent Progress in Chemically Modified siRNAs
Mini-Reviews in Medicinal Chemistry Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective Enzyme Inhibitors
Current Drug Targets Effects of Specific Cyclooxygenase-2 Inhibitors on Carcinogenesis
Medicinal Chemistry Reviews - Online (Discontinued) Vitamin D and Vitamin D Receptor Activators in Treatment of Hypertension and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Unfolded Protein Response is Involved in Trans-Platinum (II) Complex-Induced Apoptosis in Prostate Cancer Cells via ROS Accumulation
Anti-Cancer Agents in Medicinal Chemistry New Cell Therapy Using Bone Marrow-Derived Stem Cells/Endothelial Progenitor Cells to Accelerate Neovascularization in Healing of Experimental Ulcerative Colitis
Current Pharmaceutical Design Vascular Disrupting Agents (VDAs) in Anticancer Therapy
Current Clinical Pharmacology Liquid-based Cytology With HPV Triage of Low-grade Cytological Abnormalities Versus Conventional Cytology in Cervical Cancer Screening
Current Pharmaceutical Design Structural Characterization, Homology Modeling and Docking Studies of ARG674 Mutation in MyH8 Gene Associated with Trismus-Pseudocamptodactyly Syndrome
Letters in Drug Design & Discovery Patent Selections
Recent Patents on Anti-Cancer Drug Discovery In Silico Prediction of Novel Inhibitors of the DNA Binding Activity of FoxG1
Medicinal Chemistry Genistein Inhibits Cell Growth and Invasion Through Regulation of miR-27a in Pancreatic Cancer Cells
Current Pharmaceutical Design